GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

Rating:
Buy ACHN
down 23.49 %

Achillion Pharmaceuticals, Inc. (ACHN) rated Buy with price target $18 by Maxim Group

Posted on: Monday,  Feb 25, 2013  8:25 AM ET by Maxim Group

Maxim Group rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 02/25/2013, when the stock price was $8.64. Since then, Achillion Pharmaceuticals,
Inc. has lost 23.50% of its value until Maxim Group rated ACHN Hold on 07/02/2013, when the price was $6.61.
If you would have followed this Maxim Group's recommendation on ACHN, you would have lost 23.49% of your investment in 127 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/13/2015 8:25 AM Buy
None
7.86 11.00
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD down  -17.47 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/15/2014 12:00 AM Buy
None
9.25
3/24/2014 8:25 AM Buy
None
3.61 6.00
7/2/2013 8:25 AM Hold
None
6.61
2/25/2013 8:25 AM Buy
None
8.64 18.00
6/13/2012 8:25 AM Buy
None
6.35 12.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy